MedTrace Logo

A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.

NCT00381082 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2006-12-12

No results posted yet for this study

Summary

Objective

To compare the cure rates (defined as the complete absence of live lice, adults or nymphs, as diagnosed by wet-combing of three Australian approved head lice products for the treatment of primary school children with head lice infestation. The study design will be randomised and assessor-blind using three comparative parallel treatment groups.

The study population will consist of Queensland state primary school children (up to Year 7) with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice product in the four weeks prior to the study.

Conditions

  • Pediculosis

Interventions

DRUG

1) MOOV Head Lice Treatment (Ego Pharmaceutical).

DRUG

Banlice Mousse Aerosol (Pfizer, Australia)

DRUG

3) KP24 Medicated Foam (Nelson Laboratories)

Sponsors & Collaborators

  • Ego Pharmaceuticals

    collaborator INDUSTRY

  • Uniquest Pty Ltd

    lead OTHER

Principal Investigators

  • Stephen Barker, PhD · The University of Queensland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Completion
2004-11-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00381082 on ClinicalTrials.gov